Evidence map›Paper›PMID 25276202›Full record

ArticleIranian journal of pharmaceutical research : IJPR2014

A Randomized Clinical Trial Study: Anti-Oxidant, Anti-hyperglycemic and Anti-Hyperlipidemic Effects of Olibanum Gum in Type 2 Diabetic Patients.

Abbas Azadmehr, Amir Ziaee, Laleh Ghanei, Hassan Fallah Huseini, Reza Hajiaghaee, Bahareh Tavakoli-Far, Gholamreza Kordafshari

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Iranian journal of pharmaceutical research : IJPR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Effect of boswellia (Frontiers in clinical diabetes and healthcare · 2024
    Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. The journey of boswellic acids from synthesis to pharmacological activities.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Effect ofIranian journal of pharmaceutical research : IJPR · 2019
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. The effect of saffron (Avicenna journal of phytomedicine
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Abbas AzadmehrMetabolic Disease Research Center, Department of Immunology, Qazvin University of Medical Sciences, Qazvin, Iran.
Amir ZiaeeMetabolic Disease Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.
Laleh GhaneiMetabolic Disease Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.
Hassan Fallah HuseiniPharmacology and Applied Medicine, Department of Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran.
Reza HajiaghaeePharmacognosy and Pharmaceutic Department of Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran.
Bahareh Tavakoli-FarDepartment of Pharmacology, Alborz University of Medical Sciences, Karaj, Iran.
Gholamreza KordafshariSchool of Traditional Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Qazvin University of Medical Sciences · IRIranian Research Institute of Plant Protection · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes is a common metabolic disease in the world that has many adverse effects. Olibanum gum resin (from trees of the genus Boswellia) has traditionally been used in the treatment of various diseases such as diabetes. The aim of this study was the comparison of Olibanum gum resin effect with placebo on the treatment of type 2 diabetes. Inclusion criteria was diabetic patients with fasting blood sugar (FBS) =140-200 mg/dL. This study has been designed as double-blined clinical trial on 71 patients with type 2 diabetes and the patients randomly were divided to interventional and placebo groups. The patients on standard anti-diabetic therapy (metformin) treated with Olibanum gum resin (400 mg caps) and placebo tow times per day for 12 weeks, respectively. At the end of the twelfth week, the FBS, HbA1c, Insulin, total Cholesterol (Chol), LDL, Triglyceride (TG), HDL and other parameters were measured. The Olibanum gum resin lowered the FBS, HbA1c, Insulin, Chol, LDL and TG levels significantly (p < 0.001, p < 0.001, p <0.001, p = 0.003, p < 0.001 and p < 0.001, respectively) without any significant effects on the other blood lipid levels and liver/kidney function tests (p > 0.05) compared with the placebo at the endpoint. Moreover, this plant showed anti-oxidant effect and also no adverse effects were reported. The results suggest that Olibanum gum resin could be used as a safe anti-oxidant, anti-hyperglycemic and anti-hyperlipidemic agent for type 2 diabetic patients.

Indexed as

DiabetesHyperglycemiaHyperlipidemiaOlibanum gum resinPatients

Identifiers

PMID25276202
PMCPMC4177622
OpenAlexW2165439890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.